Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray

Exclusion Criteria

• •1. \<30% scalp surface area
• •2. Scalp Investigator global assessment (IGA) clear or almost clear at time of screening
• •3. Any condition, which would place the subject at unacceptable risk if he/she were to participate in the study.
• •4. Pregnant or breast feeding, or considering becoming pregnant during the study.
• •5. Use of any investigational drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).
• •6. Use of oral systemic medications for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin, apremilast and cyclosporine).
• •7. Use of ustekinumab and/or anti-IL-17 (interleukin 17) biologic therapy within 24 weeks or other experimental or commercially available biologic immune modulator(s) within 12 weeks prior to the first IP dose.
• •8. Patient used other topical therapies to treat within 2 weeks of the Baseline Visit (not including permitted topical therapy for face, groin and axilla).
• •9. Patient received ultraviolet B, UVB phototherapy within 2 weeks of Baseline.
• •10. Patient received psoralen and Ultraviolet A, PUVA phototherapy within 4 weeks of Baseline.
• •11. Patient has a known hypersensitivity to the excipients of Topicort Spray® as stated in the label.